Merck and NicOx S.A. have signed an agreement to collaborate on the development of new antihypertensive drugs using NicOx’s proprietary nitric oxide-donating technology.  This agreement follows the successful completion of the companies’ research collaboration, which has generated promising results. Under the terms of the agreement, NicOx will receive an upfront payment of $11.2 million and is eligible for potential further milestone payments of $340.2 million. NicOx has the optio...